Cargando…

A pilot randomized controlled trial of WeiNaoKang (SaiLuoTong) in treating vascular dementia

OBJECTIVE: WeiNaoKang (or SaiLuoTong) is an herbal formula consisting of ginkgo, ginseng, and saffron. Our objective was to investigate if WeiNaoKang could improve cognitive function and cerebral perfusion in patients suffering from vascular dementia. METHODS: A 16‐week randomized double‐blind, plac...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Junguang, Chang, Dennis, Cordato, Dennis, Lee, Kien, Dixson, Hugh, Bensoussan, Alan, Chan, Daniel Kam Yin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9805291/
https://www.ncbi.nlm.nih.gov/pubmed/36606270
http://dx.doi.org/10.1002/agm2.12230
_version_ 1784862309416435712
author Liu, Junguang
Chang, Dennis
Cordato, Dennis
Lee, Kien
Dixson, Hugh
Bensoussan, Alan
Chan, Daniel Kam Yin
author_facet Liu, Junguang
Chang, Dennis
Cordato, Dennis
Lee, Kien
Dixson, Hugh
Bensoussan, Alan
Chan, Daniel Kam Yin
author_sort Liu, Junguang
collection PubMed
description OBJECTIVE: WeiNaoKang (or SaiLuoTong) is an herbal formula consisting of ginkgo, ginseng, and saffron. Our objective was to investigate if WeiNaoKang could improve cognitive function and cerebral perfusion in patients suffering from vascular dementia. METHODS: A 16‐week randomized double‐blind, placebo‐controlled trial was carried out in the setting of a memory disorder clinic at a single center. Patients with vascular dementia diagnosed clinically but supported by imaging and other investigations were invited to participate. The diagnoses were based on the National Institute of Neurological Disorders and Stroke/Association Internationale pour la Recherche et l'Enseignement en Neurosciences (NINDS‐AIREN) criteria. An independent blinded assessor evaluated the effects of the formula. Intervention group was compared to the control group. A subgroup of participants was randomly chosen for further evaluation of cerebral perfusion by single photon emission computed tomography scans post‐treatment. RESULTS: Both groups were comparable in age (mean = 74 ± 7.2 years in the placebo group and 75 ± 7.4 in the intervention group) and in other demographics. Sixty‐two participants were included in final analysis. Alzheimer's Disease Assessment Scale – Cognitive Portion (ADAS‐cog) was the primary outcome. By week 16, the mean ADAS‐cog reduced from 24.48 to 20.30 (mean reduction = 4.18) for those in the treatment group, and from 18.98 to 17.81 (mean reduction = 1.18) for those in the placebo group. The difference in mean reduction of ADAS‐cog was −3.00 (95% confidence interval [CI] = −4.910 to −1.100) in favor of the treatment group. Secondary outcomes of activities of daily living and quality of life measures also showed significant difference. In the perfusion scan analysis, the difference in the change in cerebral blood flow (t‐scores) pre‐ and post‐treatment between the intervention group (n = 7) and the placebo group (n = 11) was statistically significant (P < 0.001). CONCLUSION: In this randomized, double‐blind placebo‐controlled trial, we demonstrated significant differences in improvement in cognitive function and activities of daily living. The clinical improvement is corroborated with improvement in cerebral perfusion in a subset of participants.
format Online
Article
Text
id pubmed-9805291
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-98052912023-01-04 A pilot randomized controlled trial of WeiNaoKang (SaiLuoTong) in treating vascular dementia Liu, Junguang Chang, Dennis Cordato, Dennis Lee, Kien Dixson, Hugh Bensoussan, Alan Chan, Daniel Kam Yin Aging Med (Milton) Original Articles OBJECTIVE: WeiNaoKang (or SaiLuoTong) is an herbal formula consisting of ginkgo, ginseng, and saffron. Our objective was to investigate if WeiNaoKang could improve cognitive function and cerebral perfusion in patients suffering from vascular dementia. METHODS: A 16‐week randomized double‐blind, placebo‐controlled trial was carried out in the setting of a memory disorder clinic at a single center. Patients with vascular dementia diagnosed clinically but supported by imaging and other investigations were invited to participate. The diagnoses were based on the National Institute of Neurological Disorders and Stroke/Association Internationale pour la Recherche et l'Enseignement en Neurosciences (NINDS‐AIREN) criteria. An independent blinded assessor evaluated the effects of the formula. Intervention group was compared to the control group. A subgroup of participants was randomly chosen for further evaluation of cerebral perfusion by single photon emission computed tomography scans post‐treatment. RESULTS: Both groups were comparable in age (mean = 74 ± 7.2 years in the placebo group and 75 ± 7.4 in the intervention group) and in other demographics. Sixty‐two participants were included in final analysis. Alzheimer's Disease Assessment Scale – Cognitive Portion (ADAS‐cog) was the primary outcome. By week 16, the mean ADAS‐cog reduced from 24.48 to 20.30 (mean reduction = 4.18) for those in the treatment group, and from 18.98 to 17.81 (mean reduction = 1.18) for those in the placebo group. The difference in mean reduction of ADAS‐cog was −3.00 (95% confidence interval [CI] = −4.910 to −1.100) in favor of the treatment group. Secondary outcomes of activities of daily living and quality of life measures also showed significant difference. In the perfusion scan analysis, the difference in the change in cerebral blood flow (t‐scores) pre‐ and post‐treatment between the intervention group (n = 7) and the placebo group (n = 11) was statistically significant (P < 0.001). CONCLUSION: In this randomized, double‐blind placebo‐controlled trial, we demonstrated significant differences in improvement in cognitive function and activities of daily living. The clinical improvement is corroborated with improvement in cerebral perfusion in a subset of participants. John Wiley and Sons Inc. 2022-11-22 /pmc/articles/PMC9805291/ /pubmed/36606270 http://dx.doi.org/10.1002/agm2.12230 Text en © 2022 The Authors. Aging Medicine published by Beijing Hospital and John Wiley & Sons Australia, Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Liu, Junguang
Chang, Dennis
Cordato, Dennis
Lee, Kien
Dixson, Hugh
Bensoussan, Alan
Chan, Daniel Kam Yin
A pilot randomized controlled trial of WeiNaoKang (SaiLuoTong) in treating vascular dementia
title A pilot randomized controlled trial of WeiNaoKang (SaiLuoTong) in treating vascular dementia
title_full A pilot randomized controlled trial of WeiNaoKang (SaiLuoTong) in treating vascular dementia
title_fullStr A pilot randomized controlled trial of WeiNaoKang (SaiLuoTong) in treating vascular dementia
title_full_unstemmed A pilot randomized controlled trial of WeiNaoKang (SaiLuoTong) in treating vascular dementia
title_short A pilot randomized controlled trial of WeiNaoKang (SaiLuoTong) in treating vascular dementia
title_sort pilot randomized controlled trial of weinaokang (sailuotong) in treating vascular dementia
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9805291/
https://www.ncbi.nlm.nih.gov/pubmed/36606270
http://dx.doi.org/10.1002/agm2.12230
work_keys_str_mv AT liujunguang apilotrandomizedcontrolledtrialofweinaokangsailuotongintreatingvasculardementia
AT changdennis apilotrandomizedcontrolledtrialofweinaokangsailuotongintreatingvasculardementia
AT cordatodennis apilotrandomizedcontrolledtrialofweinaokangsailuotongintreatingvasculardementia
AT leekien apilotrandomizedcontrolledtrialofweinaokangsailuotongintreatingvasculardementia
AT dixsonhugh apilotrandomizedcontrolledtrialofweinaokangsailuotongintreatingvasculardementia
AT bensoussanalan apilotrandomizedcontrolledtrialofweinaokangsailuotongintreatingvasculardementia
AT chandanielkamyin apilotrandomizedcontrolledtrialofweinaokangsailuotongintreatingvasculardementia
AT liujunguang pilotrandomizedcontrolledtrialofweinaokangsailuotongintreatingvasculardementia
AT changdennis pilotrandomizedcontrolledtrialofweinaokangsailuotongintreatingvasculardementia
AT cordatodennis pilotrandomizedcontrolledtrialofweinaokangsailuotongintreatingvasculardementia
AT leekien pilotrandomizedcontrolledtrialofweinaokangsailuotongintreatingvasculardementia
AT dixsonhugh pilotrandomizedcontrolledtrialofweinaokangsailuotongintreatingvasculardementia
AT bensoussanalan pilotrandomizedcontrolledtrialofweinaokangsailuotongintreatingvasculardementia
AT chandanielkamyin pilotrandomizedcontrolledtrialofweinaokangsailuotongintreatingvasculardementia